Clinical Trial

Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)

Name: Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) — clinical trial record (NCT07162480)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Phase II open label study designed to evaluate the efficacy and safety of P-Sam in patients with aggressive, solid, NOTCH mutant or p63 low (B7-H4 high) R/M ACC-I patients.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-05

Trial Details

NCT Number	NCT07162480
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: AstraZeneca
Conditions	Adenoid Cystic Carcinoma
Enrollment	28 participants
Start Date	2026-04-29
Primary Completion	2029-12-31 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-04